The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐19
Open accessAbstract
The new coronavirus, classified as severe acute respiratory syndrome (SARS)-CoV-2 that emerged in Hubei province in China, causes a new coronavirus disease, which was termed COVID-19 by WHO on 11 February 2020. COVID-19 claimed more than 65 000 lives around the world by 5th of April 2020. It is not the first coronavirus, which infects humans; the pathogenic viruses that cause human diseases (human coronaviruses, HCoV) include 6 other members designated as SARS-CoV, middle east respiratory syndrome (MERS)-CoV, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. The clinical presentation is mainly manifested as malignant pneumonia; although many patients present neurological symptoms, such as vomiting, dizziness, headache and delirium.1 Human coronaviruses were first identified in the mid-1960s; they were named for the crown-like spikes on their surface. The SARS-CoV-2 virus belongs to β-coronavirus, which also include MERS-CoV, SARS-CoV-1, NCoV-OC43 and HCoV-HKU1. The primary target cells for SARS-CoV-2 are the epithelial cells of the respiratory and gastrointestinal tract, which contain angiotensin converting enzyme 2 (ACE2), that is utilized by the virus to enter the cell; it is, however, hard to believe that the penetration of the viral agent into the organism is limited only to these tissues.2 Clinical and pre-clinical data from studies with other coronaviruses suggest wider tissue invasiveness and an evident neurotropism, which may result in more complex clinical scenarios. Can the SARS-CoV-2 enter the central nervous system (CNS) and infect neural cells? And if yes, how the CNS damage contributes to pathophysiology of the COVID-19, to its signs, symptoms and progression as well as to its sequelae. In other words, if the SARS-CoV-2 virus had a significant neurotropism, could its presence in the CNS be pathophysiologically relevant? It has been demonstrated that coronaviruses, and especially β-coronaviruses to which the SARS-CoV-2 belongs, do not limit their presence to the respiratory tract and frequently invade the CNS. This propensity has been convincingly documented for the SARS-CoV, MERS-CoV and the coronavirus responsible for porcine haemagglutinating encephalomyelitis (HEV 67N).3-5 Previous findings demonstrate that ACE2 represents the key, but not the exclusive, site of entry of the virus into the cell. The ACE2 is expressed in the brain, being in particularly present in the brain stem and in the regions responsible for regulation of cardiovascular function including subfornical organ, paraventricular nucleus, nucleus of the tractus solitarius, and rostral ventrolateral medulla; expression of ACE2 was found in both neurones and glia.6, 7 Non-ACE2 pathways for virus infection of neural cells also cannot be excluded; the marked penetration of coronavirus into the liver, an organ with lower levels of ACE 2 compared to the CNS, strongly supports the assumption that the cell entry routes can vary.8 Be this all as it may, the CNS infection with both SARS-CoV-1, MERS-CoV have been reported2 and SARS-CoV-1 has been identified in neurones from tissues obtained from infected patients.9 The intranasal administration of SARS-CoV-110 or MERS-COV11 resulted in the rapid invasion of viral particles into the brain, possibly through the olfactory bulb via trans-synaptic route. This pathway when virus enters peripheral nerves and spreads to the CNS through synaptic contacts has been well-documented for several viruses including CoVs.12 The brainstem, which hosts the respiratory neuronal circuit in the medulla, was severely infected with both types of viruses, which may contribute to degradation and failure of respiratory centres. When the nasal infecting charges were delivered in extremely low doses, only the CNS was colonized, with virus being absent in other tissues including lungs,11 corroborating the potent neurotropism of these coronarovirus strains. This testifies a viral property which cannot be ignored for a complete understanding of the impact of the β-coronaviruses on the human organism. Although direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the CNS, an ability clearly demonstrated by other members of the family to which they belong. The β-coronavirus NCoV-OC43, which causes upper respiratory tract disorder, has been found to infect neural cell lines as well as primary neurones in culture; it was also found to cause encephalitis associated with neuronal apoptosis and necrosis in mice.13 At least two cases of human encephalitis/encepahlomyelitis caused by NCoV-OC43 were also reported.14, 15 About 12% of children with clinical presentation of acute encephalitis hospitalised at the Children's Hospital of Chenzhou, China between May 2014 and April 2015 had anti-CoV antibodies in serum and in cerebrospinal fluid.16 It is of considerable interest that organ distribution studies have shown that the presence of SARS-C
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, the cytokine storm theory proposes that SARS-CoV-2 inflammatory response in the CNS is mediated by the massive glial cell cytokine release, such as IL1b, IL-6, and IFN I-III [168, 169].”
From Cognitive decline following acute viral infections: literature review and projections for post-COVID-19 (2022) · cites this paper as [169]
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337
Li, Y., Bai, W., & Hashikawa, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25728 · Cited by 2,266
Verkhratsky, A., & Nedergaard, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2016 · Cited by 1,678
Self-citationNetland, J., Meyerholz, D. K., Moore, S., Cassell, M., & Perlman, S. (2008) · Journal of Virology · doi:10.1128/jvi.00737-08 · Cited by 1,293
Ding, Y., He, L., Zhang, Q., Huang, Z., Che, X., Hou, J., Wang, H., Shen, H., Qiu, L., Li, Z., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1560 · Cited by 1,082
Gaunt, E. R., Hardie, A., Claas, E. C. J., Peter Simmonds, K., & Templeton, K. E. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00636-10 · Cited by 699
Xu, J., Zhong, S., Liu, J., Li, L., Li, Y., Wu, X., Li, Z., Deng, P., Zhang, J., Zhong, N. S., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/444461 · Cited by 492
Immunoneuropsychiatry — novel perspectives on brain disorders
Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0174-4 · Cited by 461
Li, K., Wohlford-Lenane, C., Perlman, S., Zhao, J., Jewell, A. K., Reznikov, L. R., Gibson-Corley, K. N., Meyerholz, D. K., & McCray, P. B. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv499 · Cited by 459
Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43
Dubé, M., Le Coupanec, A., Wong, A. H. M., Rini, J. M., Desforges, M., & Talbot, P. J. (2018) · Journal of Virology · doi:10.1128/jvi.00404-18 · Cited by 452
Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses
Meertens, L., Labeau, A., Dejarnac, O., Cipriani, S., Sinigaglia, L., Bonnet-Madin, L., Le Charpentier, T., Hafirassou, M. L., Zamborlini, A., Cao-Lormeau, V.-M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.045 · Cited by 450
Sankowski, R., Mader, S., & Valdés-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
Yeh, E. A., Collins, A. R., Cohen, M. E., Duffner, P. K., & Faden, H. S. (2004) · PEDIATRICS · doi:10.1542/peds.113.1.e73 · Cited by 329
Sasannejad, C., Ely, E. W., & Lahiri, S. (2019) · Critical Care · doi:10.1186/s13054-019-2626-z · Cited by 326
Verkhratsky, A., Parpura, V., Vardjan, N., & Zorec, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_3 · Cited by 320
Self-citationHuman Coronavirus OC43 Associated with Fatal Encephalitis
Morfopoulou, S., Brown, J. R., Davies, E. G., Anderson, G. W., Virasami, A. K., Qasim, W., Chong, W. K., Hubank, M. J. F., Plagnol, V., Desforges, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509458 · Cited by 276
A model of the ACE2 structure and function as a SARS-CoV receptor
Prabakaran, P., Xiao, X., & Dimitrov, D. S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.081 · Cited by 206
Li, Y., Li, H., Fan, R., Wen, B., Zhang, J., Cao, X., Wang, C., Song, Z., Li, S., Li, X., et al. (2016) · Intervirology · doi:10.1159/000453066 · Cited by 203
Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice
Jacomy, H., Fragoso, G., Almazán, G., Mushynski, W. E., & Talbot, P. J. (2006) · Virology · doi:10.1016/j.virol.2006.01.049 · Cited by 197
Li, Y., Bai, W., Hirano, N., Hayashida, T., Taniguchi, T., Sugita, Y., Tohyama, K., & Hashikawa, T. (2012) · The Journal of Comparative Neurology · doi:10.1002/cne.23171 · Cited by 157
De La Garza, R. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.016 · Cited by 153
Angiotensin-Converting Enzyme 2: Central Regulator for Cardiovascular Function
Xia, H., & Lazartigues, E. D. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0105-7 · Cited by 149
Li, Y.-C., Bai, W.-Z., Hirano, N., Hayashida, T., & Hashikawa, T. (2012) · Virus Research · doi:10.1016/j.virusres.2011.12.021 · Cited by 148
Li, Y., Bai, W., & Hashikawa, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25824 · Cited by 134
Gowrisankar, Y. V., & Clark, M. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13641 · Cited by 92
McNeil, J. B., Hughes, C. G., Girard, T. D., Ware, L. B., Ely, E. W., Chandrasekhar, R., & Han, J. H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226412 · Cited by 72
Neurotropism of Human Coronavirus 229E
Talbot, P. J., Ékandé, S., Cashman, N. R., Mounir, S., & Stewart, J. N. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2996-5_52 · Cited by 69
Tick-Borne Encephalitis Virus Infects Rat Astrocytes but Does Not Affect Their Viability
Potokar, M., Korva, M., Jorgačevski, J., Avšič-Županc, T., & Zorec, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086219 · Cited by 59
Self-citationAstrogliopathology in the infectious insults of the brain
Zorec, R., Avšič‐Županc, T., & Verkhratsky, A. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.08.003 · Cited by 45
Self-citationJorgačevski, J., Korva, M., Potokar, M., Lisjak, M., Avšič‐Županc, T., & Zorec, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44559-8 · Cited by 45
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G. D. H., Voors, A. A., Osterhaus, A. D. M. E., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,160
Avula, A., Nalleballe, K., Narula, N., Sapozhnikov, S., Dandu, V., Toom, S., Glaser, A., & Elsayegh, D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.077 · Cited by 558
“Although ACE-2 receptors are present in the nervous system, alternate pathways have been proposed to explain the entry of SARS-CoV-2 into the nervous system, including direct injury to the blood and blood brain barrier, hypoxic injury, and immunerelated injury (Steardo et al., 2020; Wu et al., 2020).”
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Self-citationCOVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital
Thakur, K. T., Miller, E. H., Glendinning, M. D., Al‐Dalahmah, O., Banu, M. A., Boehme, A. K., Boubour, A., Bruce, S. S., Chong, A. M., Claassen, J., et al. (2021) · Brain · doi:10.1093/brain/awab148 · Cited by 396
Belli, S., Balbi, B., Prince, I., Cattaneo, D., Masocco, F., Zaccaria, S., Bertalli, L., Cattini, F., Lomazzo, A., Negro, F. D., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02096-2020 · Cited by 321
“Indeed, COVID-19 patients suffer from multiple symptoms during hospitalization, and the acute care takes place in strict isolation, which will reduce patient’s mobility to zero ([2]).”
Background
Metadata
- Authors
- Steardo, L., Steardo, L., Zorec, R., & Verkhratsky, A.
- Affiliations
- University of Ljubljana (SI)
- Ikerbasque (ES)
- Corresponding author
- Verkhratsky, Alexei
- Venue
- Acta Physiologica
- Publisher
- Wiley
- Published
- 2020-04-11
- Volume
- 229
- Issue
- 3
- Pages
- e13473-e13473
- ISSN
- 1748-1708 (ISSN-L)
- 1748-1716
- PMC
- PMC7228251
- OpenAlex
- W3013521296
- Cited by
- 367
- References
- 31
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 15 · 2023: 52 · 2022: 66 · 2021: 104 · 2020: 116
- FWCI
- 36.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Acta Physiologica (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Ljubljana (University of Ljubljana) (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 pandemic, central nervous system infection, neurotropism, central nervous system infiltration, SARS-CoV-2 pathophysiology, neurological symptoms, ACE2, betacoronaviruses, SARS-CoV-1, MERS-CoV, SARS-CoV-2 pathogenesis, clinical features
- MeSH terms
- Betacoronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Brain, Central Nervous System Infections, Humans, Peptidyl-Dipeptidase A, Neurons, Pneumonia, Viral, Coronavirus Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review